Transforming the treatment paradigm in the
costliest cancer to become the new standart-of-care in a market that has seen little innovation in >30 years
Restoring anti-tumor responses with an oral immune training agent to boost efficacy of immunotherapies for the 80% of patients unable to benefit today
Reprogramming Salmonella with bespoke synthetic circuits to deliver diverse therapeutic cargo for difficult-to-treat cancers
Bladder cancer is one of the costliest cancers to treat with 550.000 new cases annually worldwide, representing 5% of all new cases in the US. The clinical staging is determined by the depth of tumor invasion into the bladder wall and more than 70% of patients are diagnosed at an early stage, known as non-muscle invasive bladder cancer (NMIBC). Despite early diagnosis, and treatment with standard-of-care Bacillus Calmette-Guerin (BCG), up to 80% of patients recur increasing the risk of progression. Because of bladder cancer’s high incidence, frequent recurrences, and low number of treatment options, a huge unmet medical need remains.
Discovery
Preclinical
IND-enabling
Phase 1
Phase 2
Lead oncology program entering the clinic in the US in H2 2023
Discovery
Preclinical
IND-enabling
Phase 1
Phase 2
First-in-class oral training agent ready to enter the clinic in late-2023
Seeking partnership and licensing opportunities to combine with advanced immunotherapies
Discovery
Preclinical
IND-enabling
Phase 1
Phase 2
Discovery cargo-delivery platform
Discovery
Preclinical
IND-enabling
Phase 1
Phase 2
Oral, bivalent vaccine funded by Wellcome Trust
